Your browser doesn't support javascript.
loading
The effects of Nardosinone on levodopa intervention in the treatment of Parkinson's disease.
Liu, Mengmeng; Xue, Jingwen; Cao, Yuxin; Hao, Zhuangzhuang; Wang, Yuqing; Li, Jiayuan; Jiang, Tingyue; Shi, Jinli.
Afiliação
  • Liu M; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Xue J; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Cao Y; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Hao Z; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Wang Y; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Li J; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Jiang T; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Shi J; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. Electronic address: shijl@vip.sina.com.
Biomed Pharmacother ; 174: 116448, 2024 May.
Article em En | MEDLINE | ID: mdl-38522241
ABSTRACT

BACKGROUND:

The roots and rhizomes of Nardostachys jatamansi DC. are reported to be useful for the treatment of Parkinson's disease (PD). Previous research has also shown that Nardosinone, the main active component isolated from Nardostachys jatamansi DC., exhibits the potential to treat PD. AIM OF THE STUDY To investigate how the effects of Nardosinone could assist levodopa in the treatment of PD, how this process changes the intestinal flora, and to explore the effective forms of Nardosinone in the intestinal flora. MATERIAL AND

METHODS:

We used behavioral experiments, and hematoxylin-eosin staining and immunohistochemical staining, to investigate the effects of a combination of Nardosinone and levodopa on rotenone-induced PD rats. In addition, we used LC/MS-MS to determine the levels of levodopa, 5-hydroxytryptamine, dopamine and its metabolite 3, 4-dihydroxyphenylacetic acid, and homovanillic acid, to investigate the effect of the intestinal flora on co-administration in the treatment of PD. LC/MS-MS was also used to detect the metabolites of Nardosinone on the gastrointestinal tract and intestinal flora.

RESULTS:

The behavioral disorders and neuronal damage associated with PD were significantly improved following the co-administration. Analysis also revealed that the co-administration increased the levels of five neurotransmitters in the striatum, plasma and feces. In vitro experiments further demonstrated that the levels of dopamine and levodopa were increased in the intestinal flora. In total, five metabolites of Nardosinone were identified.

CONCLUSION:

Our findings indicate that Nardosinone and its metabolites might act as a potential adjutant to enhance the efficacy of levodopa via the intestinal flora, thus expanding the therapeutic potential of the combination of Chinese and Western medicine as a treatment method for PD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Levodopa / Ratos Sprague-Dawley / Microbioma Gastrointestinal Limite: Animals Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Levodopa / Ratos Sprague-Dawley / Microbioma Gastrointestinal Limite: Animals Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China